论文部分内容阅读
目的 :评价GM1 在缺血性脑卒中患者急性期应用的治疗作用。方法 :急性脑血栓形成患者 41例 ,治疗组 2 1例 ,对照组 2 0例 ,分别在治疗前后采用美国国立卫生研究院卒中评分法 (NISS)对病人进行神经功能评分 ,并采用日常生活活动 (ADL)量表 (Barthel指数 ) ,对治疗后病人的日常生活活动的能力进行评分。结果 :治疗组病人神经功能评分改善较对照组有明显差异 (P <0 0 1 ) ,日常生活活动能力提高也明显优于对照组。结论 :在缺血性脑卒中急性期添加使用GM1 能减轻病人神经功能受损程度。
Objective: To evaluate the therapeutic effect of GM1 in the acute phase of ischemic stroke. Methods: A total of 41 patients with acute cerebral thrombosis, 21 patients in the treatment group and 20 patients in the control group were enrolled in this study. The neurological function scores of the patients were assessed by NHS Stroke Scale (NISS) before and after treatment. The daily activities (ADL) scale (Barthel Index) to assess the patient’s ability to perform daily activities after treatment. Results: The improvement of neurological function score of the treatment group was significantly different from that of the control group (P <0.01), and the improvement of activities of daily living was significantly better than that of the control group. Conclusion: The addition of GM1 in the acute phase of ischemic stroke can reduce the degree of neurological impairment in patients.